C. Max Schmidt, MD, PhD, MBA, FACS

Professor of Surgery, Surgery and Biochemistry/Molecular Biology
Vice Chair of Academic Affairs

Specialty: General Surgery

Residency: The Johns Hopkins Hospital

Fellowship: The Johns Hopkins Hospital (Pancreaticobiliary Surgery)

Director, IU Health Pancreatic Cyst and Cancer Early Detection Center

Director, IU Health Pancreaticobiliary Robotic Program


Dr. C. Max Schmidt, MD, PhD, MBA, FACS,  is Associate Professor of Surgery and Associate Professor of Biochemistry and Molecular Biology with tenure at Indiana University School of Medicine.  He received his medical and business education at the University of Chicago receiving his MD and MBA in 1992.   He completed general surgical residency as well as pancreaticobiliary fellowship at Johns Hopkins Hospital in 2001.  He also received his PhD in Physiology and Biophysics from Georgetown University in 1998.  He currently holds national office as the President of the Association for Academic Surgery Foundation (AASF) and recently served three year term as the Treasurer for the Association for Academic Surgery (AAS).  He serves on several other national surgical organization committees/councils including the Society for University Surgeons  (SUS), Society for Surgery of the Alimentary Tract (SSAT), Central Surgical Association (CSA) and the Midwest Surgical Association (MSA).  He co-directs an international outreach program to teach the fundamentals of surgical research in France and is developing a similar initiative in Germany.  Dr. Schmidt is an attending surgeon at Indiana University Hospital with a practice focused on patients with pancreaticobiliary disease. He is an internationally recognized expert on precancerous cystic lesions of the pancreas.  He serves on the International Committee which develops the International Consensus Guidelines for the Treatment of Cystic Lesions of the Pancreas.  He is Surgical Director of the Indiana University Health Pancreas Cyst and Cancer Early Detection Center  which coordinates the care and follow-up of over 1000 patients with precancerous cystic lesions of the pancreas.  He also directs the Robotic Pancreaticobiliary Surgery Program at Indiana University Health.  Dr. Schmidt is the Director of Education for Research in the Department of Surgery at Indiana University.  Dr. Schmidt performs clinical trials and translational research directed at discovering novel biomarkers and targeted treatments of patients with pancreatic and liver neoplasia.  His research is or has been continuously funded for 10+ years.  Funding sources have included the National Institutes of Health (NIH), Veteran’s Affairs (VA), American Cancer Society (ACS), American Association for Cancer Research (AACR), Pancreatic Cancer Action Network (PanCAN) and Lustgarten Foundation.  He is Founder of the company “B9” which specializes in the development of “benign” biomarkers of disease.  In the community, Dr. Schmidt was recently featured on the cover of Indianapolis Magazine as a 2012 Top Doc and is one of three finalists for the 2013 Indianpolis Business Journal’s Health Care Heroes Award. He has been happily married for 23 years and has 5 children ages 18, 16, 15, 14, 7.


C. Max Schmidt CV


IU Health Physicians


IU Health Methodist/IU Health University
IU Health West

Location Information

IU Health University Hospital, Surgery OP Clinic

550 N University Blvd, #1295

Indianapolis, IN 46202

Clinical Interests


Accepting New Patients

Schedule an Appointment  Clinical Trials

Clinical Research Interests: Director of the Indiana University Health Pancreatic Cyst and Cancer Early Detection Center (PCC-EDC) which coordinates the care and follow-up of over 1000 patients with precancerous lesions of the pancreas.

Internationally recognized expert on precancerous "cysts" of the pancreas (intraductal papillary mucinous neoplasms and mucinous cystic neoplasms).

Director of the IU Health Robotic Pancreaticobiliary Surgery Program: performs minimally invasive, laparoscopic and robotic pancreaticoduodenectomy (whipple), distal pancreatectomy and other complex alimentary tract cases (hepatectomy, gastrectomy, etc.).


Basic Research Interests:

Dr. Schmidt performs clinical trials and translational research directed at discovering novel biomarkers and targeted treatments of patients with pancreatic and liver neoplasia. His research is also focused on pancreatic cancer early detection. He directs the IU Health Pancreatic Cyst and Cancer Early Detection Center (PCC-EDC). The mission of the PCC-EDC is to prevent pancreatic cancer through rigorous identification, tracking and treatment of patients "at risk" for pancreatic cancer through a multidisciplinary screening clinic, registry, community outreach, education and research discovery. There are at present 4 components to Center:

  • IU Health Pancreas Cyst and Cancer Early Detection Clinic (PCC-EDC)
  • IU-Regenstrief Pancreatic Cyst Registry (PCR)
  • IU Pancreatic Tissue Fluid Bank (PTB)
  • IU Pancreatic Cyst Biomarker Discovery Lab (PCL)

Dr. Schmidt's research has been funded by the National Institutes of Health (NIH), the Veteran's Affairs (VA), the American Cancer Society (ACS), the American Association for Cancer Research (AACR), the Pancreatic Cancer Action Network (PanCAN) and the Lustgarten Foundation.

For more information about Dr. Schmidt's research, please contact him directly via email maxschmi(at) or by phone 317-372-9011 (cell).


Research Page



  1. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: Alterations in Guanine Nucleotide Regulatory Protein Expression and Activity in Human Hepatocellular Carcinoma, Hepatology 1997; 26:1189-1194.
  2. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: Increased MAPK Expression and Activity in Primary Human Hepatocellular Carcinoma, Bioch Biophy Res Comm 1997; 236(1): 54-58.
  3. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV: Altered Expression of Mitogen-activated Protein Kinases in a Rat Model of Experimental Hepatocellular Carcinoma, Hepatology 1997; 26(6): 1484-1491.
  4. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: The Role of Adenylyl Cyclase Linked MAPK Signaling in the Regulation of Human Hepatocellular Carcinoma, Surg Forum 1998; X(477): 1-3.
  5. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: Altered Gq/G11 Guanine Nucleotide Regulatory Protein Expression in a Rat Model of Hepatocellular Carcinoma: Role in Mitogenesis.  Hepatology 1999; 29(2): 371-378.
  6. McKillop IH, Vyas N, Schmidt CM, Cahill PA, Sitzmann JV: Enhanced Gi-protein-mediated Mitogenesis following Chronic Ethanol Exposure in a Rat Model of Experimental Hepatocellular Carcinoma, Hepatology 1999; 29(2): 412-420.
  7. Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV: The Role of cAMP-MAPK Signalling in the Regulation of Human Hepatocellular Carcinoma Growth In Vitro, Eur J Gastro Hep 1999; 11(12): 1393-1399.
  8. McKillop IH, Schmidt CM, Cahill PA, Sitzmann JV: Inhibitory Guanine Nucleotide Regulatory Protein Activation of Mitogen-activated Protein Kinase in Experimental Hepatocellular Carcinoma In Vitro. Eur J Gastro Hep 1999; 11(7): 761-768.
  9. Schmidt CM, Wang Y, Wiesenauer C: Novel Combination of Cyclooxygenase-2 and MEK Inhibitors in Human Hepatocellular Carcinoma Provides a Synergistic Increase in Apoptosis, J Gastrointest Surg 2003; 7(8): 1024-1033.
  10. Yip-Schneider MT, Wiesenauer CA, Schmidt CM: Inhibition of the Phosphatidylinositol 3’-kinase Signaling Pathway Increases the Responsiveness of Pancreatic Carcinoma Cells to Sulindac, J Gastrointest Surg 2003; 7(3): 354-363.  (Top 5 most cited articles by Journal in 2003).
  11. Yip-Schneider MT, Schmidt CM: MEK Inhibition of Pancreatic Carcinoma Cells by U0126 and its Effect in Combination with Sulindac, Pancreas 2003; 27(4): 337-344.
  12. Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM: Multiple Anticancer Effects of Blocking MEK-ERK Signaling in Hepatocellular Carcinoma, J Am College of Surg 2004; 198(3): 410-421.
  13. Yip-Schnedier MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM: Parthenolide and Sulindac Cooperate to Mediate Growth Suppression and Inhibit the Nuclear Factor-kappa B Pathway in Pancreatic Carcinoma Cells, Mol Cancer Ther 2005; 4(4): 587-594.
  14. Eppstein AC, Sandoval JA, Klein PJ, Woodruff HA, Grosfeld JL, Hickey RJ, Malkas LH, Schmidt CM: Differential Sensitivity of Chemoresistant Neuroblastoma Subtypes to MAPK-Targeted Treatment Correlates with ERK, p53 Expression and Signaling Response to U0126, J Pediatr Surgery, 2006; 41:252-259.
  15. Schmidt CM, Klein PJ, Wiesenauer CA, Choi JN, Gage EA, Yip-Schneider MT, Wiebke EA, Wang Y, Omer C, Sebolt-Leopold JS: The Effects of a Novel MEK PD184161 on MEK-ERK Signaling and Growth in Human Liver Cancer, Neoplasia, 2006; Jan 8:1-8.
  16. Sandoval J, Schmidt CM. Proteomic Analysis of Neuroblastoma Subtypes in Response to MAPK Inhibition: Profiling Multiple Targets of Cancer Kinase Signaling, 2006; J Surg Res, 134(1):61-7.
  17. Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, Schmidt CM: Parthenolide Cooperates with NS398 to Inhibit Growth of Human Hepatocellular Carcinoma Cells Through Effects on Apoptosis and G0/G1 Cell Cycle Arrest, Mol Cancer Res, 2006; 4(6): 387-399.
  18. Schmidt CM, Crowell PL, Yip-Schneider MT, Savage JJ, Hertzler DA, Cummings WO: Cyclooxygenase-2-Expression Throughout Hamster and Human Pancreatic Neoplasia, Neoplasia, 2006; 8(6): 437- 445.
  19. Holcomb B, Yip-Schneider M, Schmidt CM: The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy.Pancreas. 2008 Apr;36(3):225-35. Review. featured on the cover of Pancreas April 2008 Vol 36 Issue 3.
  20. Vegeler R, Yip-Schneider MT, Schmidt CM: Effect of Targeting COX-2 and NF-kB with Celecoxib       and a Novel NF-kB Inhibitor, LC-1, in a Hamster Model of Lung Adenocarcinoma. J Surg Res. 2007   Nov;143(1):169-76.
  21. Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM:  Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo, 2007; Mol Cancer Ther. 2007 Jun;6(6):1736-44. (Designated as a “Featured Article” of Mol Cancer Ther Journal).
  22. Schmidt CM, Yip-Schneider MT, Lillemoe KD: PGE2 in Pancreatic Cyst Fluid Helps Differentiate IPMN from MCN and Predict IPMN Dysplasia. J Gastrointest Surg. 2008 Feb;12(2):243-9.
  23. Holcomb BH, Schmidt CM:  Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies J Gastrointest Surg. 2008 Feb;12(2):288-96.
  24. Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, Schmidt CM.Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-α-transgenic mice. J Gastrointest Surg. 2008 Jan;12(1):30-7.
  25. J Choi, F Albertin, CA Wiesenauer, MT Yip-Schneider, E Gage, PJ Klein, KD Lillemoe, CM Schmidt. Doxorubicin Effect on MEK-ERK Signaling Predicts its Efficacy in HCC. J Surg Res. 2008 Dec;150(2):219-26.


  1. Andersen RM, Lyttle CS, Kohrman CH, Levey GS, Neymarc K, Schmidt CM: National Study of Internal Medicine Manpower XVII: Changes in the Characteristics of Internal Medicine Residents and their Training Programs, Annals of Internal Medicine 1990; 113(3): 243-249.
  2. Lyttle CS, Andersen RM, Neymarc K, Schmidt CM, Kohrman CH, Levey GS: National Study of Internal Medicine Manpower XVIII: Subspecialty Fellowships with a Special Look at Hematology and Oncology, Annals of Internal Medicine 1991; 114(1): 36-42.
  3. Schmidt CM, Horton KM, Sitzmann JV, Jones B, Bayless T: Simple Radiographic Evaluation of Ileoanal Pouch Volume, Dis Colon Rectum, 1996; 39: 66-73.
  4. Hou MC, Lin HC, Kuo BI, Lee FY, Schmidt CM, Lee SD: Clinical Implications of the White Nipple Sign and Its Role in the Diagnosis of Esophageal Variceal Hemorrhage, Am J Gastro 1996; 91(10): 2103-2109.
  5. Schmidt CM, Lazenby AJ, Hendrickson RJ, Sitzmann JV: Preoperative Terminal Ileal and Colonic Resection Histopathology Predicts Risk of Pouchitis in Patients after Ileoanal Pull-through Procedure, Annals of Surgery 1998; 227(5) 654-665.
  6. Schmidt CM, Talamini MA, Kaufman HS, Lillemoe KD, Learn PA, Bayless T: Laparoscopic Surgery for Crohn’s Disease: Reasons for Conversion, Annals of Surgery 2001; 233(6): 733-739.
  7. Kovach SJ, Hendrickson RJ, Cappadona CR, Schmidt CM, Groen K, Konaiaris LG, Sitzmann JV: Cryoablation of Unresectable Pancreatic Cancer, Surgery 2002; 131(4): 463-464.
  8. Schmidt CM, Wiesenauer CA, Cummings OW, Yiannoutsos CT, Howard TJ, Wiebke EA, Goulet RJ, McHenry LH, Sherman S, Lehman GA, Cramer H, Madura JA: Preoperative Predictors of Malignancy in Pancreatic Intraductal Papillary Mucinous Neoplasms, Arch Surg 2003; 138(6): 610-617.
  9. Stanton KJ, Sidner RA, Miller GA, Cummings OW, Schmidt CM, Howard TJ, Wiebke EA: Analysis of Ki-67 Antigen Expression, DNA Proliferative Fraction and Survival in Resected Cancer of the Pancreas, Am J Surg 2003, 186(5): 486-492.
  10. Madura JA, Yum MN, Lehman GA, Sherman S, Schmidt CM: Mucin Secreting Cystic Lesions of the Pancreas: Treatment by Enucleation, Am Surg 2004; 70(2): 106-112.
  11. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke EA, Wiesenauer CA, Baumgardner JA, Cummings OW, Jacobson LE, Broadie TA, Canal DF, Goulet RJ jr, Curie EA, Cardenes H, Watkins JM, Loehrer PJ, Lillemoe KD, Madura JA: Pancreaticoduodenectomy: A 20-year Experience in 516 Patients, Arch Surg 2004; 139(7): 718-727.
  12. Howard TJ, Moore SA, Matthews DE, Saxena R, Schmidt CM, Wiebke EA: Pancreatic Duct Strictures are a Common Cause of Recurrent Pancreatitis after Successful Management of Pancreatic Necrosis, Annals of Surg 2004; 136(4):909-916.
  13. Krouse R, Mohler MJ, Wendel CS, Grant M, Baldwin CM, Rawl S, McCorkle R, Rosenfeld KE, Ko CY, Schmidt CM, Coons SJ: The VA Ostomy Health-Related Quality of Life Study: Objectives, Methods, and Patient Sample, Current Medical Res and Opinions, 2006; 22(4): 781-791.
  14. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, Madura JA, Wiebke EA, Lillemoe KD: A Margin-Negative R0 Resection Accomplished with Minimal Postoperative Complications is the Surgeon’s Contribution to Long-term Survival in Pancreatic Cancer, 2006; J Gastroint Surg; 10(10): 1338-1346.
  15. Pais SA, Attasaranya S, LeBlanc JK, Sherman S, Schmidt CM, DeWitt J: The Role of EUS in the Diagnosis of Intraductal Papillary Mucinous Tumors: Correlation with Surgical Histopathology, 2007; Clin Gastroenterol Hepatol;5(4):489-95.
  16. Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, Schmidt CM: Positron Emission Tomography and CT of Cystic Pancreatic Masses. Clin Radiol. 2007 Aug;62(8):745-51.
  17. Krouse RS, Grant M, Wendel CS, Mohler MJ, Rawl SM, Baldwin CM, Coons SJ, McCorkle R, Ko CY, Schmidt CM.  A Mixed-Methods Evaluation of Health-Related Quality of Life for Male Veterans with and without Intestinal Stomas.  Dis Colon Rectum 2007 Dec; 50(12):2054-2066.
  18. Schmidt CM, Glant J, Winter JM, Kennard J, Dixon J, Zhao Q, Howard TJ, Madura JA, Nakeeb A, Pitt HA, Cameron JL, Yeo CJ, Lillemoe KD. Total Pancreatectomy (R0 Resection) Improves Survival Over Sub-Total Pancreatectomy in Isolated Neck Margin Positive Pancreatic Adenocarcinoma. Surgery. 2007 Oct;142(4):572-8; discussion 578-80.
  19. Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, Howard TJ, Zyromski NJ, Nakeeb A, DeWitt JM, Akisik FM, Sherman S, Pitt HA, Lillemoe KD.  Intraductal Papillary Mucinous Neoplasms: Predictors of Malignant and Invasive Pathology. Ann Surg. 2007 Oct;246(4):644-
  20. Mathur A, Pitt HA, Marine M, Saxena R, Schmidt CM, Howard TJ, Nakeeb A, Zyromski NJ, Lillemoe KD.Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg. 2007 Dec;246(6):1058-64.
  21. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF: Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia. Am J Pathol. 2007 Apr 26; [Epub ahead of print]
  22. Shen C, Breen TE, Dobrolecki LE, Schmidt CM, Sledge GW, Miller KD, Hickey RJ.  Comparison of Computational Algorithms for the Classification of Liver Cancer using SELDI Mass Spectrometry: A Case Study.  Cancer Informatics 2007; 3: 339-349.
  23. Schmidt CM, Waters JA, Lillemoe KD: CT vs. MRCP: Optimal Classification of IPMN Type and Extent. J Gastrointest Surg. 2008 Jan;12(1):101-9.
  24. Mitchell KA, Rawl SM, Schmidt CM, Grant M, Ko CY, Baldwin CM, Wendel C, Krouse RS.  Demographic, Clinical, and Quality of Life Variables Related to Embarrassment in Veterans Living With an Intestinal Stoma. J Wound Ostomy Continence Nurs 2007 September/October; 34(5):524-532.
  25. Schmidt CM, Matos JM, Crowell PL, Howard TJ, Cummings OW, Wiebke EA, Madura JA, Loehrer PJ Sr: A Phase II Trial of Perillyl Alcohol in Patients with Resectable Pancreatic Cancer. J Surg Res. 2008 Jun 15;147(2):194-9.

Department of Surgery | 545 Barnhill Drive, Emerson Hall 203, Indianapolis, In 46202 | Phone: (317) 274-5771